Home » Stocks » Catalent

Catalent, Inc. (CTLT)

Stock Price: $94.02 USD 0.62 (0.66%)
Updated Oct 23, 2020 4:03 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 15.47B
Revenue (ttm) 3.09B
Net Income (ttm) 220.70M
Shares Out 164.51M
EPS (ttm) 1.14
PE Ratio 82.47
Forward PE 40.65
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $94.02
Previous Close $93.40
Change ($) 0.62
Change (%) 0.66%
Day's Open 93.80
Day's Range 92.21 - 94.30
Day's Volume 544,630
52-Week Range 31.04 - 96.38

More Stats

Market Cap 15.47B
Enterprise Value 17.53B
Earnings Date (est) Nov 3, 2020
Ex-Dividend Date n/a
Shares Outstanding 164.51M
Float 162.53M
EPS (basic) 1.16
EPS (diluted) 1.14
FCF / Share -0.17
Dividend n/a
Dividend Yield n/a
Earnings Yield 1.21%
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.61M
Short Ratio 0.59
Short % of Float 0.99%
Beta 1.58
PE Ratio 82.47
Forward PE 40.65
P/FCF Ratio n/a
PS Ratio 5.00
PB Ratio 5.30
Revenue 3.09B
Operating Income 394.40M
Net Income 220.70M
Free Cash Flow -25.50M
Net Cash -2.06B
Net Cash / Share -12.55
Gross Margin 31.78%
Operating Margin 12.75%
Profit Margin 5.60%
FCF Margin -0.82%
ROA 3.67%
ROE 7.62%
ROIC 7.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (13)

Buy 9
Overweight 1
Hold 3
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$102.80*
(9.34% upside)
Low
91.0
Current: $94.02
High
120.0
Target: 102.80
*Average 12-month price target from 10 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2020201920182017201620152014201320122011
Revenue3,0942,5182,4632,0751,8481,8311,8281,8001,6951,532
Revenue Growth22.89%2.22%18.7%12.3%0.94%0.17%1.52%6.22%10.64%-
Gross Profit983805753655588615599569559502
Operating Income394274269234218260241204198186
Net Income22113783.6011011221216.20-49.60-24.40-54.00
Shares Outstanding155146133125125124117117--
Earnings Per Share1.140.900.630.870.891.750.21-0.66-0.32-0.72
EPS Growth26.67%42.86%-27.59%-2.25%-49.14%733.33%----
Operating Cash Flow44024837530015517217813887.9099.70
Capital Expenditures-466-218-175-139-138-141-122-120-102-83.30
Free Cash Flow-25.5030.1020016017.6030.8056.8018.10-14.1016.40
Cash & Equivalents95334541028813215174.40106139-
Total Debt3,0182,9592,7212,0801,8611,8812,7112,6922,684-
Net Cash / Debt-2,065-2,614-2,311-1,791-1,729-1,730-2,636-2,585-2,545-
Assets7,7776,1844,5313,4543,0913,1383,0902,9503,139-
Liabilities4,2713,8963,4442,7312,4552,5043,4623,3603,490-
Book Value2,8991,6821,087724636634-371-411-351-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Catalent, Inc.
Country United States
Employees 13,900
CEO John R. Chiminski

Stock Information

Ticker Symbol CTLT
Stock Exchange New York Stock Exchange
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NYSE: CTLT
IPO Date July 31, 2014

Description

Catalent, together with its subsidiaries, provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral vector gene therapy; formulation, development, and manufacturing for parenteral dose forms, including prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. It has a collaboration with the Janssen Pharmaceutical Companies; and a partnership with Arcturus Therapeutics Holdings Inc. to support the manufacture of LUNAR-COV19. Catalent, Inc. was founded in 2007 and is headquartered in Somerset, New Jersey.